Top Page
Trinity Biotech
(NASDAQ:TRIB)
Trinity Biotech (TRIB) vs. SPDR S&P 500 ETF (SPY)
Trinity Biotech Business Overview & Revenue Model
Trinity Biotech Earnings Call Summary
Trinity Biotech Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 48.65M | 61.55M | 56.83M | 62.52M | 81.15M | 101.98M |
| Gross Profit | 16.86M | 21.44M | 19.45M | 22.05M | 33.45M | 48.58M |
| EBITDA | -18.49M | -16.91M | -24.10M | -16.71M | 10.59M | 3.19M |
| Net Income | -36.91M | -31.79M | -24.02M | -41.00M | 875.00K | -6.39M |
Balance Sheet | ||||||
| Total Assets | 103.71M | 103.29M | 59.44M | 92.10M | 118.89M | 130.40M |
| Cash, Cash Equivalents and Short-Term Investments | 1.34M | 5.17M | 3.69M | 6.58M | 25.91M | 27.33M |
| Total Debt | 117.20M | 100.76M | 67.43M | 72.20M | 99.16M | 104.34M |
| Total Liabilities | 158.43M | 138.47M | 83.38M | 94.28M | 119.21M | 132.62M |
| Stockholders Equity | -54.72M | -35.18M | -23.95M | -2.18M | -319.00K | -2.22M |
Cash Flow | ||||||
| Free Cash Flow | -4.19M | -14.26M | -12.36M | -6.90M | 4.55M | 13.56M |
| Operating Cash Flow | -1.35M | -4.19M | -11.56M | -921.00K | 13.24M | 23.75M |
| Investing Cash Flow | -8.18M | -22.97M | 24.76M | -5.98M | -8.69M | -10.20M |
| Financing Cash Flow | 8.05M | 28.81M | -16.04M | -12.32M | -6.02M | -2.72M |
Trinity Biotech Technical Analysis
Trinity Biotech Risk Analysis
Trinity Biotech Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $14.64M | -0.98 | -223.45% | ― | 3.26% | 65.96% | |
56 Neutral | $45.66M | -30.80 | -9.76% | ― | 30.95% | 59.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | $5.71M | -0.06 | -245.18% | ― | -27.66% | 13.18% | |
41 Neutral | $13.28M | -0.30 | ― | ― | -4.35% | -6.31% | |
40 Underperform | $16.18M | -0.10 | -78.22% | ― | -13.84% | 88.80% |
Trinity Biotech Corporate Events
On December 22, 2025, Trinity Biotech entered into a second amendment to its Sixth Amended and Restated Credit Agreement with Perceptive Credit Holdings III, L.P., adding a further $5 million term loan, extending the facility’s maturity to January 15, 2027, and replacing a planned non-convertible note with a convertible promissory note that allows up to $60 million of principal to be converted into ADSs at a discount to market price, subject to a floor of $1.03 and a 9.9% ownership cap. On the same date, Trinity Biotech and its subsidiary TRIB Biosensors Inc. also reached a conversion rights agreement with Perceptive Credit Holdings II, L.P. that allows a $5 million milestone payment and a renegotiated $7.5 million contingent payment tied to the Waveform acquisition to be settled, in whole or in part, in ADSs at VWAP-based prices, effectively equitizing a significant portion of the group’s debt obligations and contingent liabilities; if all conversion rights under these arrangements are exercised at the floor price, the company could issue up to about 69.9 million ADSs, materially diluting existing shareholders but improving liquidity and pushing out debt maturities.
The most recent analyst rating on (TRIB) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Trinity Biotech stock, see the TRIB Stock Forecast page.
On December 23, 2025, Trinity Biotech filed a Form 6-K with the U.S. Securities and Exchange Commission furnishing its unaudited condensed consolidated interim financial statements as of June 30, 2025 and for the six months ended June 30, 2025 and 2024, along with management’s discussion and analysis of results, liquidity and cash flows. The filing, signed by interim chief financial officer Susan O’Connor, updates investors on the company’s mid‑year financial position and performance and incorporates the information by reference into existing registration statements, underscoring its relevance for current and prospective shareholders monitoring Trinity Biotech’s capital structure and operating trends.
The most recent analyst rating on (TRIB) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Trinity Biotech stock, see the TRIB Stock Forecast page.
On December 23, 2025, Trinity Biotech announced a major order for 9 million units of its WHO-prequalified TrinScreen HIV rapid test, to be produced via its newly WHO-approved outsourced manufacturing process and delivered across the fourth quarter of 2025 and the first quarter of 2026, signaling a strong rebound in global HIV testing demand and reinforcing the company’s positioning in infectious disease diagnostics. In the same update, the company reported a 32% sequential revenue jump to $14.3 million in the third quarter of 2025, improved gross margins to 45.2%, and a return to positive adjusted EBITDA of $0.5 million, highlighted progress under its Comprehensive Transformation Plan, outlined further operational efficiencies and product pipeline advances in diabetes and oncology-related diagnostics, and announced a finance leadership transition as Paul Murphy was promoted to interim chief financial officer following the completion of Susan O’Connor’s interim term.
The most recent analyst rating on (TRIB) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Trinity Biotech stock, see the TRIB Stock Forecast page.
On December 15, 2025, Trinity Biotech announced that it has secured regulatory clearances in multiple countries and expanded the global rollout of its next-generation high-capacity HbA1c column system for its FDA-cleared Premier Hb9210 analyzer, which is now available in more than 10 countries including the United States. The upgraded column technology, aimed at the more than $2 billion and growing global laboratory HbA1c market, delivers up to four times the testing capacity of the existing system, reduces downtime and maintenance through greater column stability, and incorporates new software-driven automation to improve workflow efficiency and cut operating costs for clinical laboratories. By boosting throughput, recurring revenue potential and margins while reinforcing the Premier Hb9210’s positioning as a gold-standard, high-specificity HbA1c platform, the rollout strengthens Trinity Biotech’s competitive foothold in global diabetes care and supports its strategy to deepen market penetration and drive long-term value for stakeholders.
The most recent analyst rating on (TRIB) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Trinity Biotech stock, see the TRIB Stock Forecast page.
On November 18, 2025, Trinity Biotech announced it received World Health Organization approval for the offshored and outsourced manufacturing of its Uni-Gold rapid HIV test. This approval is a significant milestone in the company’s transformation plan aimed at enhancing profitability. The strategic move to offshore manufacturing is expected to improve gross margins, EBITDA, and cash flow, while maintaining product integrity and compliance. This initiative reflects the leadership’s capability to execute strategic transformations and positions the company for long-term growth by reducing costs and focusing on innovation.
The most recent analyst rating on (TRIB) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Trinity Biotech stock, see the TRIB Stock Forecast page.
On November 14, 2025, Trinity Biotech announced a strategic collaboration with a leading bioinformatics company to enhance the EpiCapture prostate cancer test through advanced epigenetic analysis. This collaboration aims to improve the test’s ability to monitor prostate cancer progression non-invasively, potentially reducing the need for invasive procedures and improving patient care. The EpiCapture test, currently in late-stage development, has shown promise in accurately predicting high-grade cancers and is part of Trinity Biotech’s strategy to expand its portfolio of innovative diagnostic technologies.
The most recent analyst rating on (TRIB) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Trinity Biotech stock, see the TRIB Stock Forecast page.
At the Annual General Meeting on September 30, 2025, Trinity Biotech’s shareholders approved amendments to the company’s Constitution, which were subsequently disclosed. Additionally, the company and its subsidiaries amended their credit agreement with Perceptive Credit Holdings III, L.P., reflecting a strategic financial adjustment. These changes are indicative of Trinity Biotech’s efforts to refine its corporate governance and financial strategies, potentially impacting its operational flexibility and stakeholder relations.
The most recent analyst rating on (TRIB) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Trinity Biotech stock, see the TRIB Stock Forecast page.